diarrhea-predominant irritable bowel syndrome Classification code 10023003
Conditions
Interventions
Product Name: ramosetron hydrochloride
Product Code: YM060
Pharmaceutical Form: Tablet
INN or Proposed INN: ramosetron
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration numbe
Sponsors
Yamanouchi Europe B.V.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: At study entry (visit 1): 1. Patient who signs written informed consent. 2. Male or female patient aged between 18-70 years. 3. a. Patient meets Rome II criteria for IBS(2) , i.e.: at least 3 weeks or more, which need not be consecutive, in the preceding 3 months of abdominal discomfort or pain that has two out of three following features: (1) Relieved with defecation; and/or (2) Onset associated with a change in frequency of stool; and/or (3) Onset associated with a change in form (appearance) of stool b. Patient is identified as having d-IBS, i.e.: one or more of question 2, 4 or 6 from the Questions and Rules to Identify d-IBS Patient (Appendix 5) are rated 2 or above, and questions 1, 3 and 5 are rated 0 or 1. 4. Patient in whom organic disease has been ruled out after being diagnosed with IBS, within 5 years prior to the run-in, by a sigmoidoscopic (for patients =65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Patient will be excluded from participation if any of the following apply: At study entry (visit 1): 1. Patient with a history of surgical resection of the stomach, small intestine or large intestine (excluding resection of the appendix or benign polyps) 2. Patient with a history of inflammatory intestinal diseases (Crohn’s disease or ulcerative colitis) 3. Patient with a history of ischemic colitis 4. Patient with infectious enteritis 5. Patient with any disease, other than IBS, potentially affecting the digestive tract passage or colonic function 6. Patient requiring treatment with any of the non-permitted drugs which has not been safely stopped 3 days prior to the 2-week run-in period 7. Patient who has a history of drug or alcohol abuse within 1 year prior to the start of this clinical trial 8. Patient with malignant melanoma and any non-skin malignancy within 5 years prior to the start of this clinical trial 9. Patient with thyroid dysfunction 10. Patient receiving radiotherapy for abdominal disease 11. Patient with severe cardiovascular disease, respiratory diseases, renal diseases, hepatic diseases, digestive tract diseases (excluding IBS), blood diseases, or neurological or psychiatric diseases 12. Female of child-bearing potential without using a medically acceptable method of birth control (medically acceptable methods of birth control are: intra-uterine devices, vaginal device, contraceptive pills of combination type, contraceptive patch, barrier method, hormonal implants and injectable contraceptives, or female being surgically sterile or being at least 1-year postmenopausal) 13. Pregnant woman or lactating mother or woman with an intention of pregnancy 14. Participation in any clinical study within 3 months, or participation in more than 3 clinical studies within 12 months, prior to visit 1 15. Known allergy to the study drug, any of its components or any other 5-HT3 antagonists. 16. Any clinical condition which, in the opinion of the investigator would not allow safe completion of the study 17. Employee of the Yamanouchi Group or CRO involved in the study At randomization (visit 2): 18. Patient reported having any Type 1 or Type 2 stool on the Bristol Stool Form Scale during the run-in period (see Appendix 6 for the detailed description and illustration of the Bristol Stool Form Scale). 19. Patient with fewer than three bowel movements per week in the 2-week run-in period 20. Pregnant woman as determined by the positive pregnancy test result 21. Patient who has recently experienced lactose intolerance. 22. Patient with abnormal laboratory test or positive stool cultures (e.g., C. difficile, ova and parasites, Camplylobacter, E. Coli 0157:H7, Yersinia, Salmonella, Shigella), which is judged to be clinically significant. 23. Patient who takes contraindicated concomitant drugs (see Appendix 1)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To investigate the potential efficacy, safety and tolerability of different oral doses of YM060 in patients with diarrhea-predominant irritable bowel syndrome;Secondary Objective: To identify dose(s) for future phase III clinical studies To obtain data on population pharmacokinetics ;Primary end point(s): · Responder rate of global assessment of relief of overall IBS symptoms during the last 4 weeks of treatment · Responder rate of global assessment of relief of abdominal discomfort/pain during the last 4 weeks of treatment Definitions of responder: IBS symptoms relief: Patient-reported Global assessment of relief of overall IBS symptoms (question #10 in Appendix 4) with a score of 0 or 1 for at least 2 weeks of the last 4 weeks treatment. Abdominal discomfort/pain relief: Patient-reported Global assessment of relief of abdominal discomfort/pain (question #11 in Appendix 4) with a score of 0 or 1 for at least 2 weeks of the last 4 weeks of treatment. | — |
Countries
Estonia, Lithuania
Outcome results
None listed